• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Single-arm trials for US Food and Drug Administration cancer drug approvals: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.

作者信息

Nierengarten Mary Beth

出版信息

Cancer. 2023 Jun 1;129(11):1626. doi: 10.1002/cncr.34830.

DOI:10.1002/cncr.34830
PMID:37158643
Abstract
摘要

相似文献

1
Single-arm trials for US Food and Drug Administration cancer drug approvals: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.用于美国食品药品监督管理局癌症药物批准的单臂试验:尽管使用单臂研究进行加速药物批准存在一些挑战,但它在将先前已获批用于其他用途的药物带给患者方面能发挥作用。:尽管使用单臂研究进行加速药物批准存在一些挑战,但它在将先前已获批用于其他用途的药物带给患者方面能发挥作用。
Cancer. 2023 Jun 1;129(11):1626. doi: 10.1002/cncr.34830.
2
Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.分析美国食品和药物管理局批准的抗癌药物随机临床试验中的对照臂质量。
JAMA Oncol. 2019 Jun 1;5(6):887-892. doi: 10.1001/jamaoncol.2019.0167.
3
Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021.2021年美国食品药品监督管理局对靶向抗癌药物的新批准和补充批准情况综述。
J Oncol Pharm Pract. 2023 Jan;29(1):191-207. doi: 10.1177/10781552221112015. Epub 2022 Jul 6.
4
Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.比较 2006 年至 2018 年期间肺癌治疗的 FDA 加速审批与常规审批路径。
PLoS One. 2020 Jul 24;15(7):e0236345. doi: 10.1371/journal.pone.0236345. eCollection 2020.
5
Efficacy evaluation of anticancer agents in single-arm clinical trials: analysis of review reports from Pharmaceuticals and Medical Devices Agency.单臂临床试验中抗癌药物的疗效评估:日本药品和医疗器械管理局审评报告分析
Acta Oncol. 2021 Feb;60(2):143-148. doi: 10.1080/0284186X.2021.1871946. Epub 2021 Jan 18.
6
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals.美国市场撤市后日本和欧洲继续批准抗癌药物:加速批准的比较研究。
Clin Transl Sci. 2024 Jul;17(7):e13879. doi: 10.1111/cts.13879.
7
Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies.基于单臂研究的 FDA 批准癌症药物的随机对照试验的可行性。
JNCI Cancer Spectr. 2021 Jun 30;5(4). doi: 10.1093/jncics/pkab061. eCollection 2021 Aug.
8
U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.2016 年至 2018 年美国食品和药物管理局批准的肺癌、结直肠癌、乳腺癌和前列腺癌抗癌药物趋势。
Int J Technol Assess Health Care. 2020;36(1):20-28. doi: 10.1017/S0266462319000813. Epub 2019 Nov 28.
9
Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias.支持 FDA 加速批准的单臂临床试验具有适度的效应量,且存在较高的偏倚风险。
J Clin Epidemiol. 2022 Aug;148:193-195. doi: 10.1016/j.jclinepi.2022.01.018. Epub 2022 Jan 31.
10
Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.多终点和审批途径的使用描绘了 FDA 肿瘤药物批准的十年历程。
Clin Cancer Res. 2013 Jul 15;19(14):3722-31. doi: 10.1158/1078-0432.CCR-13-0316. Epub 2013 May 10.